World's Best Scientists 2026 revealed!
Award Badge
Medicine
Switzerland
2023

D-Index & Metrics

Medicine

D-Index
157
Citations
136164
World Ranking
869
National Ranking
13

Research.com Recognitions

  • 2023 - Research.com Medicine in Switzerland Leader Award

Overview

Reinhard Dummer is affiliated with the University of Zurich in Switzerland and has contributed extensively to the fields of medicine and molecular biology, with a particular focus on oncology. Their research spans various subfields including oncology, molecular biology, immunology, epidemiology, and dermatology.

Dummer's work primarily covers topics such as melanoma and MAPK pathways, cancer immunotherapy and biomarkers, CAR-T cell therapy research, cutaneous melanoma detection and management, immunotherapy and immune responses, nonmelanoma skin cancer studies, and hedgehog signaling pathway studies.

The scientist has published articles in multiple high-profile journals, frequently contributing to:

  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Annals of Oncology
  • Cancers
  • Journal of the European Academy of Dermatology and Venereology

Among notable recent papers are:

  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma, 2020, New England Journal of Medicine
  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma, 2021, New England Journal of Medicine
  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, 2022, Zurich Open Repository and Archive (University of Zurich)
  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours, 2021, Annals of Oncology
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology

Collaboration forms a significant part of Dummer's research, with frequent co-authors including Paolo A. Ascierto, Dirk Schadendorf, Caroline Robert, Georgina V. Long, and Mitchell P. Levesque.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

    Frank O. Nestle;Selma Alijagic;Michel Gilliet;Yuansheng Sun

  • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

    Elise Olsen;Eric Vonderheid;Nicola Pimpinelli;Rein Willemze

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

    Cory M Johannessen;Jesse S. Boehm;So Young Kim;Sapana R. Thomas;Sapana R. Thomas

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

    Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

    Frank Stephen Hodi;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • High-throughput oncogene mutation profiling in human cancer

    Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

Frequent Co-Authors

Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Günter Burg
Günter Burg University of Zurich
Mitchell P. Levesque
Mitchell P. Levesque University of Zurich
Axel Hauschild
Axel Hauschild Kiel University
Caroline Robert
Caroline Robert University of Paris-Saclay
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Claus Garbe
Claus Garbe University of Tübingen
Georgina V. Long
Georgina V. Long University of Sydney
Lars E. French
Lars E. French Ludwig-Maximilians-Universität München
Keith T. Flaherty
Keith T. Flaherty Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in studying Medicine in the USA, a variety of related online degrees can help you advance your healthcare career. For those aiming for leadership roles in hospitals or clinics, a master's in healthcare administration online offers flexibility and affordability. This degree opens doors to management careers within the healthcare industry.

Nurses looking to reach the highest levels of clinical expertise may consider cheapest online dnp programs. These programs emphasize advanced clinical practice, leadership, and evidence-based care, supporting roles such as nurse practitioner or nurse executive.

Pharmacy professionals can take advantage of online pharmacy programs. These flexible options enable students to balance career and study while preparing for positions in clinical pharmacy, research, or academia.

Lastly, for those interested in the digital side of healthcare, him programs are vital. Health Information Management graduates are in high demand for roles involving electronic health records, data analysis, and regulatory compliance.

Exploring these online degrees broadens your career pathways within the growing and evolving field of healthcare.

Best Scientists Citing Reinhard Dummer

Trending Scientists